Sepsis – Update 2012

Schlüsselwörter

Sepsis - aktiviertes Protein C - Flüssigkeitsmanagement - Antibiotikakombination - Moxifloxacin - S2-k Leitlinien

Keywords

sepsis - activated protein C - fluid management - antibiotic combination therapy - moxifloxacin - S2-k guidelines

• Literatur

• 1 Abraham E, Laterre PF, Garg R et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353: 1332-1341
• 2 Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709
• 3 Boyd JH, Forbes J, Nakada TA et al. Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med 2011; 39: 259-265
• 4 Brunkhorst FM, Engel C, Bloos F et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358: 125-139
• 5 Brunkhorst FM, Oppert M, Marx G et al. Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis. JAMA 2012; 307: 2390-2399
• 6 Delaney AP, Dan A, McCaffrey J et al. The role of albumin as a resuscitation fluid for patients with sepsis. Crit Care Med 2011; 39: 386-391
• 7 Dellinger RP, Levy MM, Carlet JM et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327
• 8 Finfer S, McEvoy S, Bellomo R et al. Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med 2011; 37: 86-96
• 9 Kumar A, Zarychanski R, Light B et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010; 38: 1773-1785
• 10 Marti-Carvajal AJ, Sola I, Lathyris D et al. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2011; CD004388.
• 11 Marti-Carvajal AJ, Sola I, Lathyris D et al. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2012; 3 (CD004388)
• 12 Perner A, Haase A, Guttormsen AB et al. Hydroxyethyl starch 130/0.4 versus Ringer's acetate in severe sepsis. N Engl J Med 2012; Jun 27. [Epub ahead of print]
• 13 Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-1377
• 14 Siegel JP. Assessing the use of activated protein C in the treatment of severe sepsis. N Engl J Med 2002; 347: 1030-1034
• 15 Vincent JL, Bernard GR, Beale R et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 2005; 33: 2266-2277
• 16 Wiedemann HP, Wheeler AP, Bernard GR et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354: 2564-2575